Equipped With State-of-the-art Genomics Facilities, MedGenome Offers World-class Diagnostics and Research Services in the Country
BANGALORE, August 31, 2015 /PRNewswire/ --
MedGenome recently added HiseQ 4000 NGS machine to its Bangalore facility, making it the only lab in India to have this platform currently. Apart from the 10,000 sq. ft laboratory facility in Bangalore, MedGenome has a 5,000 sq. ft. lab in Cochin as well.
"We believe in being up to date with the latest technology advancements in the genomics industry," says Mr Sam Santhosh "Backed by a skilled team, we are able to deliver quality insights at global standards and build valuable IP's that impact healthcare outcomes."
The labs are set up with multiple sequencing technology platforms such as RT-PCR, Microarray, Sanger and Next Generation Sequencing (NGS) and the personnel have extensive experience in handling them. The RT-PCR is useful in testing few mutations and can be quick in providing results. Sanger is ideal for Single gene testing and is still the gold standard. NGS is ideal for multi-gene and multi sample tests and provides good accuracy. It is the most ideal for routine whole exome and whole genome sequencing. Microarrays are ideal for whole genome scans, and are a good balance of cost and complexity.
The facility provides a phlebotomy facility wherein patients can offer their blood samples for genetic testing as referenced by a clinician.
Dr Sridevi, Department of Medical Genetics, Manipal Hospitals, mentions, "It is good to see such advanced facility available in India providing variety of genetic testing offerings. The lab has maintained high standards in terms of SOPs and quality processes which makes it an ideal partner for clinicians seeking world-class services."
MedGenome is also the first lab to establish Non-Invasive Prenatal Testing (NIPT) for chromosomal disease in India. MedGenome labs are PNDT certified and has been validated to run the Panorama[TM] NIPT, the first facility in India to do so. MedGenome's laboratory infrastructure is world-class with a well-designed work flow and adequate safety and quality measures implemented, allowing it to gain an exclusive commercial license for NIPT in India from its US technology partner.
"The latest technology platforms allow us to deliver high quality test results," Dr Ramprasad, COO, MedGenome suggests "At the same time, with enhanced throughput, we are able to deliver results at a faster pace to our customers without compromising on the quality."
Supported by a strong bioinformatics team, MedGenome has set its base in Bangalore, India and has offices in San Francisco and Boston in the US.
About MedGenome
MedGenome is a genomics-based diagnostics and research company delivering the best of healthcare by decoding genetic information contained in an individual's genome. It is the first mover and market-leader in genomics-based diagnostics and research from India. MedGenome has worked with thousands of doctors, hospitals, and patients across India by applying Next Generation Sequencing (NGS) techniques to large disease cohorts in cancer, eye and neurological disorders, diabetes, cardiovascular diseases and rare cancers. For more information, visit at http://www.medgenome.com
For more details, contact
Hiranjith GH
[email protected]
+91-7022020883
Director - Corporate Planning
MedGenome Labs Pvt. Ltd.
Share this article